Investigations
Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE
Automated case report generated from contract-level risk evidence.
Executive Highlights
3 companies receive 36% of total spend
12,357 of 16,082 contracts (76.8%) have active risk signals
Supplier concentration is low (HHI 0.0935)
802 individuals (aggregate count) linked to 102 winner companies
61 individuals are linked to multiple winner companies
Person-company link evidence is available for 102 of 898 winner companies (11.4%); 796 have no link data
Award timing distribution is within expected bounds: 30.4% in Mar/Jun/Sep/Dec; 8% in December
Key Metrics
Flagged Rate
flagged_contracts / total_contracts = 12,357 / 16,082 = 76.8%
HHI Concentration
HHI = Σ s_i² = 0.0935
Interpretation: low supplier concentration
Thresholds: low < 0.15; medium 0.15-0.25; high > 0.25
| Company | Awarded value | Share |
|---|---|---|
| MERCK, S.A. | €11,114,565,012 | 28.6% |
| JANSSEN - CILAG FARMACÊUTICA LDA | €1,465,498,132 | 3.8% |
| NOVARTIS FARMA - PRODUTOS FARMACÊUTICOS S.A. | €1,411,631,184 | 3.6% |
Network Cluster Map
Main cluster focused on this entity with person-company links.
Whole Procurement Map
Global contract links across public bodies and companies
Public mode hides individual nodes and shows only connected-individual totals.
Loading network…
No connections found for the current filters.
Navigate: drag to pan, use mouse wheel to zoom, and reset view when needed.
Legend
Public body
Company
Top 30 High-Risk Contracts
Highest combined risk score, with indicator evidence.
| Contract | Date | Value | Risk | Evidence |
|---|---|---|---|---|
|
AE/2795/2025 - CABOZANTINIB (80MG+20MG) CP
12712938
|
2025-11-07 | €73,200 | 125 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=85
A2 · Late Publication
(40)
publication_date=2026-01-21 | celebration_date=2025-11-07
A5 · Threshold Splitting
(35)
base_price=73200.0 | threshold=75000.0
|
|
AD/2217/2022 - Prestação de serviços de Auditoria de Segurança ao Serviço de Gestão de sistemas e Tecnologias de Informação
9632728
|
2022-08-11 | €19,125 | 125 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=2311
A2 · Late Publication
(40)
publication_date=2022-12-21 | celebration_date=2022-08-11
A5 · Threshold Splitting
(35)
base_price=19125.0 | threshold=20000.0
|
|
AE/19445/2020 - Upgrade ao Sistema de Monitorização de Área – Tema Sinergie
7171230
|
2020-08-17 | €19,269 | 125 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=861
A2 · Late Publication
(40)
publication_date=2020-10-21 | celebration_date=2020-08-17
A5 · Threshold Splitting
(35)
base_price=19269.0 | threshold=20000.0
|
|
AD/832/2019 - Execução de obras diversas de reparação no Edifício do Lar de Doentes do IPOLFG
5642157
|
2019-04-08 | €19,900 | 125 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=3906
A2 · Late Publication
(40)
publication_date=2019-06-18 | celebration_date=2019-04-08
A5 · Threshold Splitting
(35)
base_price=19900.0 | threshold=20000.0
|
|
AD3021-2017AQUISIÇÃO CADEIAS LEVES LIVRES
3371578
|
2017-01-03 | €72,000 | 125 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=500
A2 · Late Publication
(40)
publication_date=2017-05-26 | celebration_date=2017-01-03
A5 · Threshold Splitting
(35)
base_price=72000.0 | threshold=75000.0
|
|
AD186-2017PRESTAÇÃO DE SERVIÇOS DE APOIO GERAL NA ÁREA DE LOGISTICA DO IPOLFG
3183172
|
2017-03-10 | €72,270 | 125 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=1547
A2 · Late Publication
(40)
publication_date=2017-03-29 | celebration_date=2017-03-10
A5 · Threshold Splitting
(35)
base_price=72270.0 | threshold=75000.0
|
|
AD155-2017-PRETAÇÃO DE SERVIÇOS DE COMUNICAÇÕES MOVEIS
3099122
|
2017-02-10 | €59,196 | 125 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=15543
A2 · Late Publication
(40)
publication_date=2017-03-07 | celebration_date=2017-02-10
A5 · Threshold Splitting
(35)
base_price=74500.0 | threshold=75000.0
|
|
AD1261-2016-SEGURANÇA E VIGILANCIA
2835939
|
2016-08-31 | €74,964 | 125 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=17693
A2 · Late Publication
(40)
publication_date=2016-12-30 | celebration_date=2016-08-31
A5 · Threshold Splitting
(35)
base_price=74964.0 | threshold=75000.0
|
|
AD1728-16Obras de remodelação do Hospital de dia Pediatria
2289221
|
2016-06-08 | €73,000 | 125 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=3906
A2 · Late Publication
(40)
publication_date=2016-07-13 | celebration_date=2016-06-08
A5 · Threshold Splitting
(35)
base_price=73300.0 | threshold=75000.0
|
|
Prestação de serviços de Implementação e configuração da plataforma sonho VZ
2142997
|
2016-04-08 | €74,500 | 125 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=17773
A2 · Late Publication
(40)
publication_date=2016-04-19 | celebration_date=2016-04-08
A5 · Threshold Splitting
(35)
base_price=74500.0 | threshold=75000.0
|
|
Fornecimento de Core de Rede e switch de acesso ao IPO LISBOA F.G.EPE
2114543
|
2016-03-10 | €70,746 | 125 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=19398
A2 · Late Publication
(40)
publication_date=2016-04-04 | celebration_date=2016-03-10
A5 · Threshold Splitting
(35)
base_price=74500.0 | threshold=75000.0
|
|
Ajuste direto para aquisição de BISACODIL [10 MG; SUP]
11291828
|
2025-03-07 | €681 | 120 (4) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=483
A2 · Late Publication
(40)
publication_date=2025-03-18 | celebration_date=2025-03-07
A6 · Low Competition
(20)
rule=a6_single_bidder | bidder_count=1
|
|
PQ/255/2022 Medicamentos aparelho cardiovascular
9374838
|
2022-02-28 | €6,485 | 110 (4) |
A2 · Late Publication
(40)
publication_date=2022-07-18 | celebration_date=2022-02-28
A5 · Threshold Splitting
(35)
base_price=142731.0 | threshold=150000.0
C1 · Missing Supplier NIF
(25)
rule=C1 no winner recorded: awarded contract (effective price > 0) has no supplier identified
|
|
PQ/255/2022 Medicamentos aparelho cardiovascular
9374664
|
2022-02-28 | €7,361 | 110 (4) |
A2 · Late Publication
(40)
publication_date=2022-07-18 | celebration_date=2022-02-28
A5 · Threshold Splitting
(35)
base_price=142731.0 | threshold=150000.0
C1 · Missing Supplier NIF
(25)
rule=C1 no winner recorded: awarded contract (effective price > 0) has no supplier identified
|
|
PQ/255/2022 Medicamentos aparelho cardiovascular
9374786
|
2022-02-28 | €3,339 | 110 (4) |
A2 · Late Publication
(40)
publication_date=2022-07-18 | celebration_date=2022-02-28
A5 · Threshold Splitting
(35)
base_price=142731.0 | threshold=150000.0
C1 · Missing Supplier NIF
(25)
rule=C1 no winner recorded: awarded contract (effective price > 0) has no supplier identified
|
|
Diverso Material Consumo Clinico
9132928
|
2022-02-28 | €1,800 | 110 (4) |
A2 · Late Publication
(40)
publication_date=2022-03-21 | celebration_date=2022-02-28
A5 · Threshold Splitting
(35)
base_price=74200.0 | threshold=75000.0
C1 · Missing Supplier NIF
(25)
rule=C1 no winner recorded: awarded contract (effective price > 0) has no supplier identified
|
|
Manutenção e Suporte da Plataforma Intranet
10657081
|
2024-01-26 | €16,050 | 110 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=6022
A2 · Late Publication
(40)
publication_date=2024-04-09 | celebration_date=2024-01-26
A6 · Low Competition
(20)
rule=a6_single_bidder | bidder_count=1
|
|
AE/240/2024 Medicamentos Exclusivos
10643464
|
2024-01-17 | €2,269 | 110 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=465
A2 · Late Publication
(40)
publication_date=2024-04-01 | celebration_date=2024-01-17
A6 · Low Competition
(20)
rule=a6_single_bidder | bidder_count=1
|
|
Prestação de Serviços de Manutenção e Assistência ao Software de Detecção de Vulnerabilidades (NESSUS)
10553615
|
2024-01-20 | €3,467 | 110 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=2311
A2 · Late Publication
(40)
publication_date=2024-02-12 | celebration_date=2024-01-20
A6 · Low Competition
(20)
rule=a6_single_bidder | bidder_count=1
|
|
Ajuste direto para aquisição de M51-MERCAPTOPURINA [50MG; CÁP/COMP] para suprir necessidades na área da saúde.
10898505
|
2024-01-26 | €12,670 | 105 (4) |
A2 · Late Publication
(40)
publication_date=2024-09-03 | celebration_date=2024-01-26
A5 · Threshold Splitting
(35)
base_price=147301.0 | threshold=150000.0
A6 · Low Competition
(20)
rule=a6_single_bidder | bidder_count=1
|
|
Material CC BENNASAR
10554078
|
2024-01-10 | €32,718 | 105 (4) |
A2 · Late Publication
(40)
publication_date=2024-02-12 | celebration_date=2024-01-10
A5 · Threshold Splitting
(35)
base_price=72853.0 | threshold=75000.0
A6 · Low Competition
(20)
rule=a6_single_bidder | bidder_count=1
|
|
Reagentes para a APAT e SCITOG
10527220
|
2024-01-15 | €5,851 | 105 (4) |
A2 · Late Publication
(40)
publication_date=2024-01-30 | celebration_date=2024-01-15
A5 · Threshold Splitting
(35)
base_price=146985.0 | threshold=150000.0
A6 · Low Competition
(20)
rule=a6_single_bidder | bidder_count=1
|
|
Assistência Técnica
10565909
|
2024-02-15 | €19,051 | 105 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=6426
A5 · Threshold Splitting
(35)
base_price=19105.0 | threshold=20000.0
A6 · Low Competition
(20)
rule=a6_single_bidder | bidder_count=1
|
|
Convite à apresentação de proposta ao abrigo do Acordo Quadro 2017/6 - Medicamentos do foro oncológico e imunomoduladores.
5988711
|
2018-12-21 | €396,959 | 105 (3) |
B5 · Benford's Law Deviation
(55)
chi2=25.9883 | sample_size=15606
A2 · Late Publication
(40)
publication_date=2019-10-29 | celebration_date=2018-12-21
A9 · Abnormal Price Reduction
(10)
base_price=10575839927.0 | total_effective_price=396959.0
|
|
CC/797/20525 - 1380/2025 Ajuste direto para aquisição de A726 - AMINOLEVULINATO de METILO [160 MG/G; BISN] e B941 - BUROSUMAB [20 MG/1 ML; SOL INJ]
11638089
|
2025-02-14 | €4,910 | 100 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=308
A2 · Late Publication
(40)
publication_date=2025-08-12 | celebration_date=2025-02-14
A9 · Abnormal Price Reduction
(10)
base_price=1340468.0 | total_effective_price=4910.0
|
|
Ajuste direto para aquisição de T1823 - TRASTUZUMAB DERUXTECANO [100 MG;PÓ CONC SOL INJ; FRS]
11587078
|
2025-06-20 | €15,876,800 | 100 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=522
A2 · Late Publication
(40)
publication_date=2025-07-16 | celebration_date=2025-06-20
A9 · Abnormal Price Reduction
(10)
base_price=15876800.0 | total_effective_price=0.0
|
|
Xpert BCR-ABL Ultra New
11471677
|
2025-01-29 | €145,000 | 100 (3) |
A2 · Late Publication
(40)
publication_date=2025-05-29 | celebration_date=2025-01-29
A5 · Threshold Splitting
(35)
base_price=145000.0 | threshold=150000.0
C1 · Missing Supplier NIF
(25)
rule=C1 no winner recorded: awarded contract (effective price > 0) has no supplier identified
|
|
INFLIXIMAB 100MG INJ
11462774
|
2025-04-22 | €19,550 | 100 (3) |
A2 · Late Publication
(40)
publication_date=2025-05-26 | celebration_date=2025-04-22
A5 · Threshold Splitting
(35)
base_price=19550.0 | threshold=20000.0
C1 · Missing Supplier NIF
(25)
rule=C1 no winner recorded: awarded contract (effective price > 0) has no supplier identified
|
|
AE/1360 / 2024 para aquisição LANREOTIDA 120MG INJ
10893261
|
2024-04-16 | €113,535 | 100 (3) |
A1 · Repeat Direct Award
(50)
authority_id=86 | supplier_id=85
A2 · Late Publication
(40)
publication_date=2024-08-29 | celebration_date=2024-04-16
A9 · Abnormal Price Reduction
(10)
base_price=11353500.0 | total_effective_price=113535.0
|
|
FORNECIMENTO DE REAGENTES E TECNOLOGIA PARA A SECÇÃO DE BIOLOGIA MOLECULAR DO LABORATÓRIO DE HEMATO-ONCOLOGIA
10410948
|
2023-02-09 | €145,000 | 100 (3) |
A2 · Late Publication
(40)
publication_date=2023-12-27 | celebration_date=2023-02-09
A5 · Threshold Splitting
(35)
base_price=145000.0 | threshold=150000.0
C1 · Missing Supplier NIF
(25)
rule=C1 no winner recorded: awarded contract (effective price > 0) has no supplier identified
|
Award Timeline
Monthly award volume and amendment risk signals.
| Period | Awards | Awarded value | Amendment signals |
|---|---|---|---|
| 2012-11 | 2 | €49,976 | 0 |
| 2013-01 | 4 | €53,174 | 0 |
| 2013-02 | 3 | €858,638 | 0 |
| 2013-03 | 3 | €82,594 | 0 |
| 2013-04 | 1 | €297 | 0 |
| 2013-05 | 5 | €42,234 | 0 |
| 2013-06 | 2 | €23,202 | 0 |
| 2013-07 | 3 | €149,036 | 0 |
| 2013-08 | 3 | €56,866 | 0 |
| 2013-09 | 5 | €135,075 | 0 |
| 2013-10 | 8 | €173,537 | 0 |
| 2013-11 | 3 | €22,652 | 0 |
| 2013-12 | 5 | €151,459 | 0 |
| 2014-01 | 33 | €208,565 | 0 |
| 2014-02 | 10 | €595,040 | 0 |
| 2014-03 | 18 | €608,087 | 0 |
| 2014-04 | 14 | €571,683 | 0 |
| 2014-05 | 12 | €1,060,310 | 0 |
| 2014-06 | 13 | €248,782 | 0 |
| 2014-07 | 9 | €242,945 | 0 |
| 2014-08 | 8 | €529,060 | 0 |
| 2014-09 | 6 | €205,758 | 0 |
| 2014-10 | 9 | €188,796 | 0 |
| 2014-11 | 4 | €38,678 | 0 |
| 2014-12 | 3 | €35,806 | 0 |
| 2015-01 | 7 | €269,044 | 0 |
| 2015-02 | 9 | €159,724 | 0 |
| 2015-03 | 7 | €445,282 | 0 |
| 2015-04 | 13 | €688,427 | 0 |
| 2015-05 | 15 | €962,707 | 0 |
| 2015-06 | 9 | €233,557 | 0 |
| 2015-07 | 14 | €302,491 | 0 |
| 2015-08 | 5 | €85,543 | 0 |
| 2015-09 | 5 | €319,984 | 0 |
| 2015-10 | 11 | €590,355 | 0 |
| 2015-11 | 5 | €1,365,981 | 0 |
| 2015-12 | 18 | €546,257 | 0 |
| 2016-01 | 13 | €2,755,989 | 0 |
| 2016-02 | 28 | €2,444,203 | 0 |
| 2016-03 | 16 | €2,134,890 | 0 |
| 2016-04 | 32 | €1,011,379 | 0 |
| 2016-05 | 25 | €1,230,454 | 0 |
| 2016-06 | 24 | €1,633,780 | 0 |
| 2016-07 | 20 | €1,205,541 | 0 |
| 2016-08 | 18 | €2,405,175 | 0 |
| 2016-09 | 38 | €3,336,025 | 0 |
| 2016-10 | 41 | €2,385,583 | 0 |
| 2016-11 | 28 | €1,009,428 | 0 |
| 2016-12 | 41 | €4,308,705 | 0 |
| 2017-01 | 64 | €4,422,961 | 0 |
| 2017-02 | 53 | €1,881,039 | 0 |
| 2017-03 | 62 | €7,637,243 | 0 |
| 2017-04 | 41 | €7,674,085 | 0 |
| 2017-05 | 50 | €10,196,067 | 0 |
| 2017-06 | 27 | €2,880,747 | 0 |
| 2017-07 | 24 | €980,391 | 0 |
| 2017-08 | 24 | €2,414,211 | 0 |
| 2017-09 | 21 | €1,112,282 | 0 |
| 2017-10 | 42 | €5,295,643 | 0 |
| 2017-11 | 26 | €1,701,200 | 0 |
| 2017-12 | 19 | €1,976,880 | 0 |
| 2018-01 | 72 | €11,704,376 | 0 |
| 2018-02 | 53 | €5,116,577 | 0 |
| 2018-03 | 58 | €7,901,755 | 0 |
| 2018-04 | 45 | €5,076,839 | 0 |
| 2018-05 | 37 | €3,203,626 | 0 |
| 2018-06 | 10 | €800,670 | 0 |
| 2018-07 | 28 | €590,935 | 0 |
| 2018-08 | 13 | €1,397,535 | 0 |
| 2018-09 | 24 | €797,353 | 0 |
| 2018-10 | 26 | €818,912 | 0 |
| 2018-11 | 17 | €869,419 | 0 |
| 2018-12 | 24 | €7,172,861 | 0 |
| 2019-01 | 116 | €14,242,650 | 0 |
| 2019-02 | 82 | €12,454,977 | 0 |
| 2019-03 | 52 | €8,356,881 | 0 |
| 2019-04 | 49 | €1,557,485 | 0 |
| 2019-05 | 104 | €10,617,545 | 0 |
| 2019-06 | 88 | €2,007,412 | 0 |
| 2019-07 | 55 | €1,199,819 | 0 |
| 2019-08 | 36 | €2,775,954 | 0 |
| 2019-09 | 68 | €2,458,386 | 0 |
| 2019-10 | 59 | €930,679 | 0 |
| 2019-11 | 42 | €1,692,607 | 0 |
| 2019-12 | 85 | €13,167,441 | 0 |
| 2020-01 | 124 | €40,639,171 | 0 |
| 2020-02 | 70 | €3,259,771 | 0 |
| 2020-03 | 47 | €5,254,681 | 0 |
| 2020-04 | 27 | €4,756,295 | 0 |
| 2020-05 | 37 | €6,374,171 | 0 |
| 2020-06 | 16 | €1,237,759 | 0 |
| 2020-07 | 29 | €1,339,049 | 0 |
| 2020-08 | 54 | €889,906 | 0 |
| 2020-09 | 60 | €1,093,609 | 0 |
| 2020-10 | 119 | €2,602,241 | 0 |
| 2020-11 | 60 | €1,442,195 | 0 |
| 2020-12 | 65 | €11,376,047 | 0 |
| 2021-01 | 440 | €31,340,126 | 0 |
| 2021-02 | 328 | €19,920,684 | 0 |
| 2021-03 | 374 | €13,390,687 | 0 |
| 2021-04 | 284 | €8,333,243 | 0 |
| 2021-05 | 296 | €10,284,262 | 0 |
| 2021-06 | 155 | €7,997,727 | 0 |
| 2021-07 | 145 | €6,426,355 | 0 |
| 2021-08 | 210 | €4,337,175 | 0 |
| 2021-09 | 134 | €1,977,046 | 0 |
| 2021-10 | 158 | €2,548,896 | 0 |
| 2021-11 | 125 | €4,572,011 | 0 |
| 2021-12 | 221 | €15,762,600 | 0 |
| 2022-01 | 463 | €45,612,817 | 0 |
| 2022-02 | 294 | €14,811,236 | 0 |
| 2022-03 | 323 | €14,512,672 | 0 |
| 2022-04 | 230 | €4,176,240 | 0 |
| 2022-05 | 221 | €6,820,510 | 0 |
| 2022-06 | 180 | €7,875,270 | 0 |
| 2022-07 | 154 | €6,644,408 | 0 |
| 2022-08 | 130 | €3,828,128 | 0 |
| 2022-09 | 146 | €8,574,247 | 0 |
| 2022-10 | 140 | €7,428,526 | 0 |
| 2022-11 | 174 | €6,155,978 | 0 |
| 2022-12 | 259 | €14,805,205 | 0 |
| 2023-01 | 467 | €49,613,968 | 0 |
| 2023-02 | 322 | €26,577,024 | 0 |
| 2023-03 | 316 | €22,209,352 | 0 |
| 2023-04 | 197 | €5,171,948 | 0 |
| 2023-05 | 194 | €9,652,585 | 0 |
| 2023-06 | 140 | €4,294,185 | 0 |
| 2023-07 | 154 | €4,082,364 | 0 |
| 2023-08 | 152 | €4,576,467 | 0 |
| 2023-09 | 126 | €2,621,885 | 0 |
| 2023-10 | 219 | €13,446,325 | 0 |
| 2023-11 | 146 | €9,142,963 | 0 |
| 2023-12 | 187 | €13,976,071 | 0 |
| 2024-01 | 383 | €46,407,723 | 0 |
| 2024-02 | 398 | €26,622,182 | 0 |
| 2024-03 | 307 | €22,571,818 | 0 |
| 2024-04 | 229 | €19,181,627 | 0 |
| 2024-05 | 169 | €11,560,080 | 0 |
| 2024-06 | 152 | €4,878,847 | 0 |
| 2024-07 | 166 | €10,200,713 | 0 |
| 2024-08 | 197 | €13,535,602 | 0 |
| 2024-09 | 148 | €9,868,407 | 0 |
| 2024-10 | 141 | €6,449,842 | 0 |
| 2024-11 | 149 | €9,691,521 | 0 |
| 2024-12 | 307 | €30,388,637 | 0 |
| 2025-01 | 468 | €49,894,930 | 0 |
| 2025-02 | 326 | €60,931,278 | 0 |
| 2025-03 | 244 | €20,522,194 | 0 |
| 2025-04 | 248 | €10,220,259 | 0 |
| 2025-05 | 135 | €10,167,750 | 0 |
| 2025-06 | 90 | €6,468,258 | 0 |
| 2025-07 | 164 | €6,762,374 | 0 |
| 2025-08 | 116 | €5,275,453 | 0 |
| 2025-09 | 89 | €4,146,724 | 0 |
| 2025-10 | 89 | €3,109,415 | 0 |
| 2025-11 | 66 | €3,245,590 | 0 |
| 2025-12 | 46 | €3,029,776 | 0 |
| 2026-01 | 15 | €1,536,131 | 0 |
| 2026-02 | 4 | €168,090 | 0 |
Risk scoring combines rule-based indicators with data quality flags. Values and confidence degrade when critical fields are missing.